Loading...
XJPX4569
Market cap529mUSD
Jan 17, Last price  
1,440.00JPY
1D
-0.41%
1Q
-5.01%
Jan 2017
-42.56%
IPO
0.84%
Name

Kyorin Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XJPX:4569 chart
P/E
15.54
P/S
0.69
EPS
92.64
Div Yield, %
3.64%
Shrs. gr., 5y
-2.64%
Rev. gr., 5y
1.02%
Revenues
119.53b
+5.53%
66,296,000,00074,054,000,00077,093,000,00081,070,000,00090,889,000,00099,764,000,000104,069,000,000103,232,000,000107,031,000,000111,400,000,000113,121,000,000119,483,000,000115,373,000,000110,640,000,000113,620,000,000109,983,000,000102,904,000,000105,534,000,000113,270,000,000119,532,000,000
Net income
5.32b
+12.68%
2,013,000,0005,228,000,0004,842,000,0002,189,000,0002,037,000,0008,848,000,00010,927,000,0009,231,000,00012,422,000,00012,025,000,00012,064,000,00013,639,000,0007,305,000,0006,574,000,0006,869,000,0006,149,000,0006,130,000,0003,932,000,0004,723,000,0005,322,000,000
CFO
1.55b
-22.86%
-7,346,000,00010,548,000,0005,005,000,0004,444,000,0004,575,000,00012,027,000,0006,805,000,0008,913,000,00011,544,000,00019,293,000,0006,391,000,00011,137,000,00016,386,000,00010,456,000,000340,000,0007,739,000,0005,189,000,0006,346,000,0002,008,000,0001,549,000,000
Dividend
Mar 28, 20250 JPY/sh
Earnings
Feb 04, 2025

Profile

KYORIN Holdings, Inc., through its subsidiaries, researches and develops, produces, and sells ethical and generic drugs in Japan and internationally. The company offers Flutiform, a drug for the treatment of asthma; Desalex, an antiallergic agent; Beova, Uritos, and Imidafenacin KYORIN therapeutic agents for overactive bladder; Lasvic, a quinolone synthetic antibacterial agent; Pentasa, a remedy for ulcerative colitis/Crohn's disease; Nasonex, an allergic rhinitis therapeutic agent; and Kipres, a leukotriene receptor antagonist anti-bronchial asthma and allergic rhinitis drug. It also provides Mucodyne, a mucoregulating drug; Montelukast KM, a drug for the treatment of bronchial asthma and allergic rhinitis; GeneSoC, a real-time PCR system; Rubysta, a disinfectant cleaner; Milton, a disinfectant; over-the-counter drugs; prescription medicines and quasi-drugs, diagnostics, and industrial chemicals; and reagents and intermediates. In addition, the company offers subcontracted drug manufacturing services. Further, it is involved in the discovery and evaluation of candidate compounds; and research and analysis of other companies' technologies and collection of information concerning clinical trial. KYORIN Holdings, Inc. was founded in 1923 and is based in Tokyo, Japan.
URL
https://www.kyorin-pharm.co.jp/
IPO date
Mar 10, 2006
Employees
2,138
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
119,532,000
5.53%
113,270,000
7.33%
105,534,000
2.56%
Cost of revenue
113,518,000
108,145,000
100,526,000
Unusual Expense (Income)
NOPBT
6,014,000
5,125,000
5,008,000
NOPBT Margin
5.03%
4.52%
4.75%
Operating Taxes
1,696,000
2,182,000
1,284,000
Tax Rate
28.20%
42.58%
25.64%
NOPAT
4,318,000
2,943,000
3,724,000
Net income
5,322,000
12.68%
4,723,000
20.12%
3,932,000
-35.86%
Dividends
(3,013,000)
(3,015,000)
(3,767,000)
Dividend yield
2.90%
3.09%
3.70%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
20,387,000
10,434,000
10,447,000
Long-term debt
770,000
11,184,000
11,665,000
Deferred revenue
5,000
3,228,000
Other long-term liabilities
663,000
4,759,000
655,000
Net debt
(14,934,000)
(22,245,000)
(32,522,000)
Cash flow
Cash from operating activities
1,549,000
2,008,000
6,346,000
CAPEX
(6,246,000)
(9,405,000)
(2,690,000)
Cash from investing activities
(3,187,000)
(6,275,000)
(2,560,000)
Cash from financing activities
(3,347,000)
(3,363,000)
(4,112,000)
FCF
(3,932,000)
(6,497,000)
2,352,000
Balance
Cash
13,985,000
19,394,000
27,494,000
Long term investments
22,106,000
24,469,000
27,140,000
Excess cash
30,114,400
38,199,500
49,357,300
Stockholders' equity
143,380,000
260,556,000
257,917,000
Invested Capital
121,352,600
111,269,500
100,126,700
ROIC
3.71%
2.78%
3.75%
ROCE
3.97%
3.43%
3.35%
EV
Common stock shares outstanding
57,389
57,303
57,302
Price
1,812.00
6.34%
1,704.00
-4.11%
1,777.00
-7.83%
Market cap
103,989,551
6.50%
97,644,433
-4.11%
101,825,611
-7.82%
EV
89,055,551
197,580,433
189,794,611
EBITDA
10,304,000
8,965,000
8,722,000
EV/EBITDA
8.64
22.04
21.76
Interest
66,000
66,000
66,000
Interest/NOPBT
1.10%
1.29%
1.32%